WATSON PHARMACEUTICALS INC
Form 4
December 11, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *
MIRANDA DIANE F

(Last) (First) (Middle)

C/O WATSON PHARMA, INC., 360 MOUNT KEMBLE AVENUE

(Street)

MORRISTOWN, NJ 07960

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
WATSON PHARMACEUTICALS INC [WPI]

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2009

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP,Generic Marketing & Oper.

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value $0.0033	12/10/2009		M		20,000	A	$ 28.15	34,288	D	
Common Stock, par value $0.0033	12/10/2009		M		5,653	A	$ 28.74	39,941	D	
Common Stock, par	12/10/2009		S		400	D	$ 38.2	39,541	D	

value $0.0033							
Common Stock, par value $0.0033	12/10/2009	S	600	D	$ 38.21	38,941	D
Common Stock, par value $0.0033	12/10/2009	S	1,126	D	$ 38.36	37,815	D
Common Stock, par value $0.0033	12/10/2009	S	300	D	$ 38.25	37,515	D
Common Stock, par value $0.0033	12/10/2009	S	353	D	$ 38.26	37,162	D
Common Stock, par value $0.0033	12/10/2009	S	3,000	D	$ 38.28	34,162	D
Common Stock, par value $0.0033	12/10/2009	S	1,500	D	$ 38.24	32,662	D
Common Stock, par value $0.0033	12/10/2009	S	2,500	D	$ 38.4	30,162	D
Common Stock, par value $0.0033	12/10/2009	S	4,000	D	$ 38.37	26,162	D
Common Stock, par value $0.0033	12/10/2009	S	1,068	D	$ 38.35	25,094	D
Common Stock, par value $0.0033	12/10/2009	S	10,806	D	$ 38.3	14,288 (1)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not SEC 1474 (9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Secur (Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Am or Nu of S
Non-Qualified Options to Purchase Common Stock	$ 28.15	12/10/2009		M			20,000	11/26/2004	11/26/2011	Common Stock, par value $0.0033	20
Non-Qualified Options to Purchase Common Stock	$ 28.74	12/10/2009		M			5,653	12/30/2002	12/28/2009	Common Stock, par value $0.0033	5,

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MIRANDA DIANE F C/O WATSON PHARMA, INC. 360 MOUNT KEMBLE AVENUE MORRISTOWN, NJ 07960			VP,Generic Marketing & Oper.	

Signatures

/s/DIANE F. MIRANDA	12/11/2009
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes shares of restricted stock issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.